Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
52.3M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
19.8M
-
Shares change
-
+960K
-
Total reported value, excl. options
-
$48.1M
-
Value change
-
+$2.52M
-
Put/Call ratio
-
0.51
-
Number of buys
-
14
-
Number of sells
-
-26
-
Price
-
$2.43
Significant Holders of ENZO BIOCHEM INC - Common Stock (ENZB) as of Q1 2023
66 filings reported holding ENZB - ENZO BIOCHEM INC - Common Stock as of Q1 2023.
ENZO BIOCHEM INC - Common Stock (ENZB) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.8M shares
of 52.3M outstanding shares and own 37.85% of the company stock.
Largest 10 shareholders include HARBERT FUND ADVISORS, INC. (5.18M shares), RENAISSANCE TECHNOLOGIES LLC (2.77M shares), TANG CAPITAL MANAGEMENT LLC (2.3M shares), VANGUARD GROUP INC (1.77M shares), DIMENSIONAL FUND ADVISORS LP (1.52M shares), BlackRock Inc. (1.42M shares), FULLER & THALER ASSET MANAGEMENT, INC. (983K shares), Roumell Asset Management, LLC (905K shares), Potomac Capital Management, Inc. (781K shares), and GEODE CAPITAL MANAGEMENT, LLC (355K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.